Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cisplatin

1 Oe Cisplatin. Cisplatin [civ-diammincdichloroplatinum(II)] is a clinically used chemotherapeutic agent in the treatment of a variety of human cancers. The anticancer activity of cisplatin is believed to result from cytotoxicity induced by cisplatin DNA adducts. Not surprisingly, cisplatin itself is a mutagen and carcinogen. G - T and A — T transversions appear to be the main mutations induced by cisplatin. [Pg.488]


A second family of carbohydrate-degrading enzymes, the lysozymes, produces synergistic antimetastatic activity when co-adrninistered with cisplatin [15663-27-1] to mice whose primary tumor had been surgically removed (51). [Pg.309]

Amongst these are bis(cyclopentadienyl) and bis(y3-diketonate) derivatives, some of which are undergoing clinical trials, in the hope that they will provide more extensive application than cisplatin (pp. 1163-4). [Pg.975]

Structure, recognition, and processing of cisplatin-DNA adducts 99CRV2467. [Pg.235]

Carboplatin (96) is significantly less toxic in the clinic than cisplatin. Most particularly, it is much less nephrotoxic. Use of a bidentate ligand also ensures formation of a ds complex. Its synthesis begins with cis-diammine platinum diiodide (94) which is reacted with silver sulfate to give cis-diaquodiam mine platinum sulfate (95). This is reacted with the barium salt of 1,1-cyclo-butanedicarboxylic acid to yield carboplatin [23],... [Pg.16]

The only prominent antitumor tetravalent platinum complex so far is iproplatin (102). In vitro it has been shown to cause interstrand DNA-breaking and cross linking. Free radical scavengers inhibit these effects. The complex is less neurotoxic and less nephrotoxic than cisplatin. Its synthesis begins with hydrogen peroxide oxidation of cis-dichlorobis(isopropvlamine) platinum (100) to the dimethylacetamide complex 101. The latter is heated in vacuum to liberate iproplatin [25]. [Pg.17]

Cisplatin, Pt (NH3)2Cl2, is a chemotherapeutic agent that disrupts die growth of DNA. If die current cost of Pt is 1118.0/troy ounce (1 troy oz = 31.10 g), how many grams of cisplatin can you make with three thousand dollars worth of platinum How many pounds ... [Pg.72]

The cis isomer ( cisplatin ) is an effective anticancer drug. This reflects the ability of the two Cl atoms to interact with the nitrogen atoms of DNA, a molecule responsible for cell reproduction. The trans isomer is ineffective in chemotherapy, presumably because the Q atoms are too far apart to react with a DNA molecule. [Pg.414]

When solutions containing the aqua complexes derived from cisplatin react with pyrimidines and other bases and are exposed to air, blue solutions (and solids) result [94], These are mixed-valence oligomers (n = 4). Some have anti-tumour activity but have not yet found clinical use. [Pg.209]

Figure 3.116 Platinum compounds studied for possible anti-tumour activity. I, ris-Dichlorodi-ammineplatinum(II) cisplatin, platinol NSC 119875 neoplatin platinex. II, a.s-Diammine(l,l-cyclobutanedicarboxylato)platinum(II) JM-8 paraplatin NSC 241240. Ill, Oxiplatin. IV, Tetraplatin. V, Amminediacetatodichloro(cyclohexylamine)platinum(IV). VI, cis-Dich oro-trans-dihydroxy-cis-bis(isopropylamine)platinum(IV) iproplatin JM-19 CHIP NSC 256927. Figure 3.116 Platinum compounds studied for possible anti-tumour activity. I, ris-Dichlorodi-ammineplatinum(II) cisplatin, platinol NSC 119875 neoplatin platinex. II, a.s-Diammine(l,l-cyclobutanedicarboxylato)platinum(II) JM-8 paraplatin NSC 241240. Ill, Oxiplatin. IV, Tetraplatin. V, Amminediacetatodichloro(cyclohexylamine)platinum(IV). VI, cis-Dich oro-trans-dihydroxy-cis-bis(isopropylamine)platinum(IV) iproplatin JM-19 CHIP NSC 256927.
Dimeric complexes like [Cl(NH3)Pt H2N(CH2)4NH2 Pt(NH3)Cl]Cl2 are also being investigated as they bind to DNA in a different way to that involved in cisplatin binding and are active in cisplatin-resistant human tumour cells. They are more potent than cisplatin in lung cancer models in vivo and are likely to go on clinical trials in the near future [204],... [Pg.269]

The ability of cisplatin to be toxic to tumour cells is believed to relate to its binding to DNA, but since trans- [Pt (NH3) 2 Cl2 ] also binds to DNA, the reason for the inactivity of the trans-form is more complex. [Pg.269]

Figure 3.118 Possible modes of cisplatin binding to DNA strands. (Reproduced from J.J.R. Frausto da Silva and R.J.P. Williams, The Biological Chemistry of the Elements, 1994, p. 539, by permission of Oxford University Press.)... Figure 3.118 Possible modes of cisplatin binding to DNA strands. (Reproduced from J.J.R. Frausto da Silva and R.J.P. Williams, The Biological Chemistry of the Elements, 1994, p. 539, by permission of Oxford University Press.)...
Figure 3.119 cis-Pt(NH3)2[d(pGpG)], model compound for the binding of cisplatin to DNA. (Reprinted with permission from Science, 1985,230,430. Copyright (1985) American Association for the Advancement of Science.)... [Pg.270]

Binding of cisplatin to the neighbouring bases in the DNA disrupts the orderly stacking of the purine bases when it forms a 1,2-intrastrand crosslink, it bends the DNA helix by some 34° towards the major groove and unwinds the helix by 13°. These cross-links are believed to block DNA replication. [Pg.270]


See other pages where Cisplatin is mentioned: [Pg.222]    [Pg.222]    [Pg.222]    [Pg.204]    [Pg.257]    [Pg.258]    [Pg.176]    [Pg.183]    [Pg.184]    [Pg.158]    [Pg.437]    [Pg.144]    [Pg.173]    [Pg.417]    [Pg.446]    [Pg.96]    [Pg.98]    [Pg.210]    [Pg.43]    [Pg.327]    [Pg.1164]    [Pg.16]    [Pg.235]    [Pg.99]    [Pg.203]    [Pg.267]    [Pg.268]    [Pg.269]    [Pg.269]    [Pg.269]    [Pg.270]    [Pg.270]    [Pg.271]    [Pg.383]   
See also in sourсe #XX -- [ Pg.1164 ]

See also in sourсe #XX -- [ Pg.15 , Pg.16 , Pg.17 ]

See also in sourсe #XX -- [ Pg.367 , Pg.380 , Pg.385 , Pg.388 , Pg.392 , Pg.395 , Pg.396 , Pg.423 ]

See also in sourсe #XX -- [ Pg.185 , Pg.290 , Pg.300 ]

See also in sourсe #XX -- [ Pg.541 ]

See also in sourсe #XX -- [ Pg.53 , Pg.55 , Pg.64 ]

See also in sourсe #XX -- [ Pg.102 ]

See also in sourсe #XX -- [ Pg.1291 ]

See also in sourсe #XX -- [ Pg.96 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.3 , Pg.9 , Pg.19 , Pg.20 , Pg.23 , Pg.24 , Pg.25 , Pg.49 , Pg.50 , Pg.51 , Pg.54 , Pg.60 , Pg.61 , Pg.65 , Pg.66 , Pg.69 , Pg.70 , Pg.72 , Pg.73 , Pg.77 , Pg.78 , Pg.81 , Pg.82 , Pg.83 , Pg.106 , Pg.107 , Pg.108 , Pg.113 , Pg.117 , Pg.118 ]

See also in sourсe #XX -- [ Pg.134 ]

See also in sourсe #XX -- [ Pg.201 , Pg.267 ]

See also in sourсe #XX -- [ Pg.580 ]

See also in sourсe #XX -- [ Pg.2 , Pg.4 ]

See also in sourсe #XX -- [ Pg.82 , Pg.90 ]

See also in sourсe #XX -- [ Pg.16 , Pg.136 ]

See also in sourсe #XX -- [ Pg.124 , Pg.126 ]

See also in sourсe #XX -- [ Pg.17 ]

See also in sourсe #XX -- [ Pg.388 ]

See also in sourсe #XX -- [ Pg.168 , Pg.175 , Pg.176 ]

See also in sourсe #XX -- [ Pg.2 ]

See also in sourсe #XX -- [ Pg.347 ]

See also in sourсe #XX -- [ Pg.105 , Pg.107 , Pg.109 , Pg.111 , Pg.123 ]

See also in sourсe #XX -- [ Pg.93 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.298 ]

See also in sourсe #XX -- [ Pg.402 ]

See also in sourсe #XX -- [ Pg.4 ]

See also in sourсe #XX -- [ Pg.132 , Pg.185 ]

See also in sourсe #XX -- [ Pg.113 ]

See also in sourсe #XX -- [ Pg.447 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.82 , Pg.90 ]

See also in sourсe #XX -- [ Pg.372 , Pg.379 ]

See also in sourсe #XX -- [ Pg.238 ]

See also in sourсe #XX -- [ Pg.32 ]

See also in sourсe #XX -- [ Pg.43 ]

See also in sourсe #XX -- [ Pg.559 ]

See also in sourсe #XX -- [ Pg.308 , Pg.457 ]

See also in sourсe #XX -- [ Pg.64 ]

See also in sourсe #XX -- [ Pg.490 , Pg.490 ]

See also in sourсe #XX -- [ Pg.113 ]

See also in sourсe #XX -- [ Pg.218 , Pg.224 ]

See also in sourсe #XX -- [ Pg.360 ]

See also in sourсe #XX -- [ Pg.578 , Pg.579 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.95 ]

See also in sourсe #XX -- [ Pg.51 , Pg.52 ]

See also in sourсe #XX -- [ Pg.138 , Pg.138 ]

See also in sourсe #XX -- [ Pg.408 ]

See also in sourсe #XX -- [ Pg.307 ]

See also in sourсe #XX -- [ Pg.357 , Pg.368 ]

See also in sourсe #XX -- [ Pg.167 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.340 , Pg.342 ]

See also in sourсe #XX -- [ Pg.6 ]

See also in sourсe #XX -- [ Pg.123 ]

See also in sourсe #XX -- [ Pg.217 ]

See also in sourсe #XX -- [ Pg.49 ]

See also in sourсe #XX -- [ Pg.325 ]

See also in sourсe #XX -- [ Pg.21 , Pg.24 , Pg.30 , Pg.59 , Pg.71 , Pg.119 , Pg.133 , Pg.197 , Pg.207 ]

See also in sourсe #XX -- [ Pg.487 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.112 ]

See also in sourсe #XX -- [ Pg.373 , Pg.395 , Pg.399 ]

See also in sourсe #XX -- [ Pg.385 , Pg.513 ]

See also in sourсe #XX -- [ Pg.166 ]

See also in sourсe #XX -- [ Pg.179 , Pg.206 , Pg.207 ]

See also in sourсe #XX -- [ Pg.116 , Pg.211 ]

See also in sourсe #XX -- [ Pg.300 , Pg.342 ]

See also in sourсe #XX -- [ Pg.459 , Pg.488 , Pg.725 ]

See also in sourсe #XX -- [ Pg.226 ]

See also in sourсe #XX -- [ Pg.4 ]

See also in sourсe #XX -- [ Pg.278 ]

See also in sourсe #XX -- [ Pg.201 , Pg.267 ]

See also in sourсe #XX -- [ Pg.308 , Pg.457 ]

See also in sourсe #XX -- [ Pg.72 , Pg.73 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.111 ]

See also in sourсe #XX -- [ Pg.608 ]

See also in sourсe #XX -- [ Pg.513 , Pg.514 , Pg.515 ]

See also in sourсe #XX -- [ Pg.218 , Pg.224 ]

See also in sourсe #XX -- [ Pg.143 , Pg.173 , Pg.176 ]

See also in sourсe #XX -- [ Pg.9 ]

See also in sourсe #XX -- [ Pg.404 , Pg.406 ]

See also in sourсe #XX -- [ Pg.52 ]

See also in sourсe #XX -- [ Pg.82 , Pg.90 ]

See also in sourсe #XX -- [ Pg.8 , Pg.10 , Pg.11 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.118 ]

See also in sourсe #XX -- [ Pg.52 ]

See also in sourсe #XX -- [ Pg.234 ]

See also in sourсe #XX -- [ Pg.44 , Pg.293 ]

See also in sourсe #XX -- [ Pg.14 , Pg.423 ]

See also in sourсe #XX -- [ Pg.227 ]

See also in sourсe #XX -- [ Pg.76 ]

See also in sourсe #XX -- [ Pg.80 , Pg.199 , Pg.200 , Pg.204 , Pg.207 , Pg.208 , Pg.211 , Pg.212 , Pg.213 , Pg.468 , Pg.469 ]

See also in sourсe #XX -- [ Pg.288 ]

See also in sourсe #XX -- [ Pg.201 , Pg.267 ]

See also in sourсe #XX -- [ Pg.110 ]

See also in sourсe #XX -- [ Pg.323 ]

See also in sourсe #XX -- [ Pg.240 , Pg.241 , Pg.242 , Pg.243 , Pg.245 ]

See also in sourсe #XX -- [ Pg.178 ]

See also in sourсe #XX -- [ Pg.2308 ]

See also in sourсe #XX -- [ Pg.463 ]

See also in sourсe #XX -- [ Pg.584 ]

See also in sourсe #XX -- [ Pg.334 , Pg.335 ]

See also in sourсe #XX -- [ Pg.188 ]

See also in sourсe #XX -- [ Pg.364 , Pg.377 ]

See also in sourсe #XX -- [ Pg.648 , Pg.650 , Pg.651 ]

See also in sourсe #XX -- [ Pg.1164 ]

See also in sourсe #XX -- [ Pg.95 ]

See also in sourсe #XX -- [ Pg.8 , Pg.388 ]

See also in sourсe #XX -- [ Pg.898 ]

See also in sourсe #XX -- [ Pg.129 , Pg.130 , Pg.184 , Pg.186 , Pg.187 ]

See also in sourсe #XX -- [ Pg.14 ]

See also in sourсe #XX -- [ Pg.354 , Pg.355 , Pg.356 , Pg.357 ]

See also in sourсe #XX -- [ Pg.183 ]

See also in sourсe #XX -- [ Pg.16 ]

See also in sourсe #XX -- [ Pg.53 ]

See also in sourсe #XX -- [ Pg.21 , Pg.26 , Pg.28 , Pg.30 , Pg.56 , Pg.136 , Pg.213 , Pg.559 ]

See also in sourсe #XX -- [ Pg.647 , Pg.689 ]

See also in sourсe #XX -- [ Pg.85 , Pg.159 , Pg.208 , Pg.259 , Pg.537 ]

See also in sourсe #XX -- [ Pg.136 ]

See also in sourсe #XX -- [ Pg.56 ]

See also in sourсe #XX -- [ Pg.3 , Pg.214 , Pg.225 , Pg.268 ]

See also in sourсe #XX -- [ Pg.218 , Pg.224 ]

See also in sourсe #XX -- [ Pg.213 ]

See also in sourсe #XX -- [ Pg.52 ]

See also in sourсe #XX -- [ Pg.362 , Pg.363 , Pg.365 ]

See also in sourсe #XX -- [ Pg.308 ]

See also in sourсe #XX -- [ Pg.218 , Pg.224 ]

See also in sourсe #XX -- [ Pg.457 , Pg.458 ]

See also in sourсe #XX -- [ Pg.478 , Pg.479 , Pg.481 , Pg.486 , Pg.553 ]

See also in sourсe #XX -- [ Pg.826 , Pg.827 , Pg.828 ]

See also in sourсe #XX -- [ Pg.113 ]

See also in sourсe #XX -- [ Pg.166 ]

See also in sourсe #XX -- [ Pg.124 ]

See also in sourсe #XX -- [ Pg.1156 , Pg.1163 , Pg.1164 ]

See also in sourсe #XX -- [ Pg.28 ]

See also in sourсe #XX -- [ Pg.3 , Pg.214 , Pg.225 , Pg.268 ]

See also in sourсe #XX -- [ Pg.360 ]

See also in sourсe #XX -- [ Pg.160 , Pg.161 , Pg.545 , Pg.548 ]

See also in sourсe #XX -- [ Pg.504 , Pg.564 ]

See also in sourсe #XX -- [ Pg.14 , Pg.15 , Pg.77 ]

See also in sourсe #XX -- [ Pg.284 , Pg.286 ]

See also in sourсe #XX -- [ Pg.243 ]

See also in sourсe #XX -- [ Pg.57 , Pg.60 , Pg.61 , Pg.111 , Pg.127 , Pg.131 , Pg.154 , Pg.209 , Pg.215 , Pg.309 , Pg.345 , Pg.544 , Pg.567 , Pg.568 , Pg.611 , Pg.677 ]

See also in sourсe #XX -- [ Pg.6 , Pg.40 , Pg.87 , Pg.88 ]

See also in sourсe #XX -- [ Pg.648 , Pg.650 , Pg.651 ]

See also in sourсe #XX -- [ Pg.7 , Pg.8 ]

See also in sourсe #XX -- [ Pg.101 ]

See also in sourсe #XX -- [ Pg.560 ]

See also in sourсe #XX -- [ Pg.143 , Pg.144 , Pg.145 , Pg.174 ]

See also in sourсe #XX -- [ Pg.220 , Pg.278 ]

See also in sourсe #XX -- [ Pg.201 , Pg.267 ]

See also in sourсe #XX -- [ Pg.43 ]

See also in sourсe #XX -- [ Pg.11 , Pg.48 , Pg.487 , Pg.488 ]

See also in sourсe #XX -- [ Pg.379 , Pg.982 ]

See also in sourсe #XX -- [ Pg.422 ]

See also in sourсe #XX -- [ Pg.575 ]

See also in sourсe #XX -- [ Pg.746 , Pg.794 ]

See also in sourсe #XX -- [ Pg.253 ]

See also in sourсe #XX -- [ Pg.575 ]

See also in sourсe #XX -- [ Pg.75 ]

See also in sourсe #XX -- [ Pg.178 ]

See also in sourсe #XX -- [ Pg.316 ]

See also in sourсe #XX -- [ Pg.442 , Pg.452 , Pg.455 ]

See also in sourсe #XX -- [ Pg.394 , Pg.1016 ]

See also in sourсe #XX -- [ Pg.179 , Pg.180 ]

See also in sourсe #XX -- [ Pg.483 , Pg.499 , Pg.500 , Pg.585 ]

See also in sourсe #XX -- [ Pg.374 ]

See also in sourсe #XX -- [ Pg.109 , Pg.110 , Pg.111 , Pg.112 ]

See also in sourсe #XX -- [ Pg.281 ]

See also in sourсe #XX -- [ Pg.242 ]

See also in sourсe #XX -- [ Pg.978 ]

See also in sourсe #XX -- [ Pg.24 , Pg.27 , Pg.65 , Pg.86 , Pg.91 , Pg.98 , Pg.118 , Pg.125 , Pg.126 , Pg.128 , Pg.183 ]

See also in sourсe #XX -- [ Pg.523 , Pg.524 ]

See also in sourсe #XX -- [ Pg.795 ]

See also in sourсe #XX -- [ Pg.248 ]

See also in sourсe #XX -- [ Pg.332 , Pg.742 , Pg.746 , Pg.747 , Pg.750 ]

See also in sourсe #XX -- [ Pg.182 ]

See also in sourсe #XX -- [ Pg.483 , Pg.550 ]

See also in sourсe #XX -- [ Pg.8 , Pg.40 , Pg.55 , Pg.60 , Pg.65 , Pg.69 , Pg.82 , Pg.114 ]

See also in sourсe #XX -- [ Pg.288 ]

See also in sourсe #XX -- [ Pg.163 , Pg.169 , Pg.170 , Pg.185 , Pg.195 ]

See also in sourсe #XX -- [ Pg.703 ]

See also in sourсe #XX -- [ Pg.187 ]

See also in sourсe #XX -- [ Pg.751 ]

See also in sourсe #XX -- [ Pg.564 , Pg.565 , Pg.574 , Pg.575 ]

See also in sourсe #XX -- [ Pg.489 ]

See also in sourсe #XX -- [ Pg.254 ]

See also in sourсe #XX -- [ Pg.780 , Pg.832 ]

See also in sourсe #XX -- [ Pg.312 , Pg.324 ]

See also in sourсe #XX -- [ Pg.165 , Pg.166 , Pg.167 ]

See also in sourсe #XX -- [ Pg.73 ]

See also in sourсe #XX -- [ Pg.36 , Pg.37 , Pg.50 ]

See also in sourсe #XX -- [ Pg.222 ]

See also in sourсe #XX -- [ Pg.182 ]

See also in sourсe #XX -- [ Pg.382 ]

See also in sourсe #XX -- [ Pg.5 , Pg.145 , Pg.145 , Pg.146 , Pg.146 ]

See also in sourсe #XX -- [ Pg.376 ]

See also in sourсe #XX -- [ Pg.252 ]

See also in sourсe #XX -- [ Pg.201 , Pg.267 ]

See also in sourсe #XX -- [ Pg.76 ]

See also in sourсe #XX -- [ Pg.266 , Pg.267 ]

See also in sourсe #XX -- [ Pg.1122 ]

See also in sourсe #XX -- [ Pg.32 , Pg.33 ]

See also in sourсe #XX -- [ Pg.77 ]

See also in sourсe #XX -- [ Pg.182 ]

See also in sourсe #XX -- [ Pg.244 , Pg.251 ]

See also in sourсe #XX -- [ Pg.305 ]

See also in sourсe #XX -- [ Pg.587 ]

See also in sourсe #XX -- [ Pg.357 ]

See also in sourсe #XX -- [ Pg.68 , Pg.107 , Pg.110 , Pg.112 , Pg.119 , Pg.220 , Pg.258 , Pg.259 , Pg.269 , Pg.271 , Pg.273 , Pg.286 , Pg.287 , Pg.295 , Pg.303 , Pg.405 ]

See also in sourсe #XX -- [ Pg.282 ]

See also in sourсe #XX -- [ Pg.85 , Pg.86 , Pg.87 , Pg.89 , Pg.90 ]

See also in sourсe #XX -- [ Pg.71 , Pg.72 , Pg.79 , Pg.80 , Pg.81 , Pg.84 ]

See also in sourсe #XX -- [ Pg.83 ]

See also in sourсe #XX -- [ Pg.84 ]

See also in sourсe #XX -- [ Pg.223 ]

See also in sourсe #XX -- [ Pg.1157 ]

See also in sourсe #XX -- [ Pg.151 , Pg.151 , Pg.152 , Pg.152 , Pg.153 ]

See also in sourсe #XX -- [ Pg.37 ]

See also in sourсe #XX -- [ Pg.446 ]




SEARCH



Acute kidney injury cisplatin-induced

Adenine cisplatin

Amikacin Cisplatin

Ammonia from Cisplatin

Amphotericin Cisplatin

Anticancer compounds cisplatin

Anticancer compounds cisplatin properties

Anticancer drugs cisplatin

Anticancer drugs, specific agents cisplatin

Antitumor agent, cisplatin

Apoptosis cisplatin

Aquation cisplatin

Bleomycin Cisplatin

Cancer chemotherapy cisplatin

Cancer therapy cisplatin

Carbamazepine Cisplatin

Carboplatin versus cisplatin

Carcinoma cisplatin therapy

Cell culture cisplatin

Cervical cancer cisplatin/radiation therapy

Cimetidine Cisplatin

Cisplatin (Platinol NSC

Cisplatin (also

Cisplatin (also clinical activity

Cisplatin (also discovery

Cisplatin (also pharmacology

Cisplatin (also target

Cisplatin (cis-diamminedichloroplatinum

Cisplatin 4- -receptor antagonists

Cisplatin 4- Gentamicin

Cisplatin 4- Ifosfamide

Cisplatin 4- Ondansetron

Cisplatin 4- Pemetrexed

Cisplatin 5-FU

Cisplatin Aminoglycosides

Cisplatin Diuretics, loop

Cisplatin Docetaxel

Cisplatin Etoposide

Cisplatin Furosemide

Cisplatin Gemcitabine

Cisplatin Lewis lung carcinoma

Cisplatin Methotrexate

Cisplatin Phenytoin

Cisplatin Primidone

Cisplatin Probenecid

Cisplatin Ranitidine

Cisplatin Tobramycin

Cisplatin Valproate

Cisplatin Vancomycin

Cisplatin Verapamil

Cisplatin actions

Cisplatin activation

Cisplatin activation reactions

Cisplatin adverse effects

Cisplatin alkylating agent

Cisplatin amine derivatives

Cisplatin analogues

Cisplatin and Related Complexes

Cisplatin animal models

Cisplatin anticancer agent

Cisplatin antitumour action

Cisplatin antiviral activity

Cisplatin bladder cancer

Cisplatin cancer

Cisplatin cancer chemotherapy drug

Cisplatin carcinogen

Cisplatin cellular mechanisms

Cisplatin cervical cancer

Cisplatin characterization

Cisplatin chemistry

Cisplatin chemotherapy

Cisplatin clinical administration

Cisplatin clinical pharmacology

Cisplatin clinical properties

Cisplatin combination with paclitaxel

Cisplatin complexes

Cisplatin detoxification

Cisplatin dosage

Cisplatin drug interactions

Cisplatin emetogenicity

Cisplatin encapsulation

Cisplatin extravasation

Cisplatin for cancer chemotherapy

Cisplatin gastric cancer

Cisplatin glutathione

Cisplatin half lives

Cisplatin head cancers

Cisplatin history

Cisplatin hydration

Cisplatin hydrolysis

Cisplatin hypocalcemia with

Cisplatin hypomagnesemia with

Cisplatin in lung cancer

Cisplatin in ovarian cancer

Cisplatin interaction with aminoglycosides

Cisplatin interactions

Cisplatin intra strand

Cisplatin intrastrand crosslink

Cisplatin limitations

Cisplatin liposome formulation

Cisplatin lung cancer

Cisplatin lysozyme

Cisplatin mainchain structures

Cisplatin mechanism of action

Cisplatin metabolites

Cisplatin nanocomposites

Cisplatin nasopharyngeal cancers

Cisplatin nausea/vomiting with, aprepitant

Cisplatin neck cancers

Cisplatin nephrotoxicity

Cisplatin ovarian cancer

Cisplatin pancreatitis with

Cisplatin pharmacokinetics

Cisplatin plasma protein

Cisplatin prodrug

Cisplatin properties

Cisplatin protein recognition

Cisplatin radiosensitization

Cisplatin reaction with

Cisplatin rescue

Cisplatin resistance

Cisplatin resistant cancer cell

Cisplatin resistant diseases

Cisplatin resistant model

Cisplatin sarcomas

Cisplatin selective toxicity

Cisplatin sensitivity

Cisplatin side effects

Cisplatin small-cell lung carcinoma

Cisplatin solution stability

Cisplatin structure

Cisplatin structure-activity relationship

Cisplatin testicular germ cell cancer

Cisplatin therapy

Cisplatin thermal stability

Cisplatin toxic side effects

Cisplatin toxicity

Cisplatin transport

Cisplatin treatment

Cisplatin tubular secretion

Cisplatin uptake

Cisplatin uptake treatment

Cisplatin urinary biomarkers

Cisplatin vindesine with

Cisplatin water solubility

Cisplatin with aminoglycosides

Cisplatin with gemcitabine

Cisplatin with ionizing radiation

Cisplatin with loop diuretics

Cisplatin with methotrexate

Cisplatin with tirapazamine

Cisplatin with vinblastine

Cisplatin, anticancer activity

Cisplatin, apoptosis induction

Cisplatin, cw-diamminedichloroplatinum

Cisplatin, empirical formula

Cisplatin-DNA adducts

Cisplatin-derivatives

Cisplatin-derivatives active form

Cisplatin-derivatives anticancer activity

Cisplatin-derivatives polymers

Cisplatin-induced emesis

Cisplatin-loaded micelle

Cisplatin-resistant 5637 cell lines

Cisplatin-sensitive

Cisplatin/fluorouracil

Cisplatin/fluorouracil/radiation

Cisplatin/methotrexate/vinblastine

Cisplatin/methotrexate/vinblastine/doxorubicin

Cisplatin/paclitaxel

Cisplatin/radiation therapy

Cisplatine

Cisplatine

Clinical activity of cisplatin

Clozapine cisplatin

Coordination chemistry cisplatin

Cysteine cisplatin

Cytostatic agents cisplatin

DNA cisplatin

Day Cisplatin Chemotherapy

Dendrimer cisplatin

Drugs cisplatin

Emesis, antagonists cisplatin-induced

Glutathione interaction with cisplatin

Glutathione reaction with cisplatin

Glycol/cisplatin

Guanine cisplatin

Guanine, cisplatin compounds

Hydration cisplatin therapy

Hydrolysis of Cisplatin

Interactions Between DNA and Cisplatin

Irinotecan + cisplatin

Ligand binding of cisplatin

Mechanism of cisplatin

Methionine cisplatin

Nucleic acids cisplatin

Nucleic acids reaction of cisplatin with

Ototoxicity from cisplatin

Ototoxicity of cisplatin

Paclitaxel and cisplatin

Pharmacokinetics cisplatin compounds

Plasma proteins cisplatin binding

Platinol - Cisplatin

Platinum anticancer drugs cisplatin

Platinum anticancer drugs, chemistry cisplatin

Platinum cisplatin properties

Platinum complexes cisplatin mechanism

Platinum compounds cisplatin analogues

Platinum drug cisplatin

Platinum, cisplatin

Polymers cisplatin properties

Properties of Cisplatin

Reaction of cisplatin with

Second generation of cisplatin analogs

Selective toxicity cisplatin/carboplatin

Structure-activity relationships, cisplatin compounds

Toxicity cisplatin compounds

Toxicity of cisplatin

Tumor cells, with acquired resistance cisplatin

Tumor therapy cisplatin

© 2024 chempedia.info